Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Leukemia Clinical Trials

Protocol Number Title
1999LS060
MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
1999LS073
MT1999-20 Hematopoietic cell transplantation in children with juvenile myelomonocytic leukemia
2003NT036
ALTE03N1 Key Adverse Events After Childhood Cancer (COG study)
2005LS064
MT2003-02R Long-Term Follow-up of Patients who have been Registered for a Hematopoietic Stem Cell Transplant or other Stem Cell Infusion
2005LS075
MT2005-25 Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
2009NTCG026
COG ALTE05N1 - Umbrella Long-Term Follow-Up Protocol
2009NTCG044
COG ALTE07C1 - Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
2009NTLS130
HM2018-16R Hematologic Disorder Tissue Bank
2010NTLS145
MT2007-05R Late Effects in Survivors of Cancer, Stem Cell Transplantation or Blood Disorders From Digital Upgrade to Digital Revolution: A New Era in Survivor Research
2012OC065
MT2012-11C: Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
2013LS023
MT2014-23R: Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation
2013NTLS082
Family-based studies of myeloid disorders and related conditions
2013NTUC039
BMT Long-Term Follow-up Study -2
2013NTUC125
MT2013-36R: PIDTC 6904: Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (PIDTC 6904)
2013OC003
MT2013-06C : Treatment of graft Failure after HSCT
2013OC013
MT2013-09C : Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases
2014CG123
MT2016-21 : COG AALL1331 - Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) "AALL1331 - Amgen, Inc."
2014LS020
MT2014-12:Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl?) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease
2014NTLS071
Family-based studies of susceptibility to early onset disease
2015CG031
ACCL1333/CV185-155 - A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Asparaginase
2015CG096
COG AAML1331 - A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid
2015LS034
MT2015-29 : Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Adult Unrelated Donor for the Treatment of Hematological Disorders
2015LS149
MT2015-17 :Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen
2015LS152
MT2015-32 : Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases
2015NTCG168
COG APEC14B1 The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study Additional Title: EVERYCHILD (APEC14B1) PCR - COG Foundation
2015NTIS003
MT2015-16R:Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
2015NTLS018
MT2015-08R: Microbial, Graft and Host Interactions in Hematopoietic Cell Transplantation Reducing sepsis-related mortality in cancer patients through microbiome therapy
2015NTLS158
An advance care planning intervention for adolescent and young adult patients undergoing bone marrow transplant
2016CG084
COG ALTE1621 - Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial Additional Title: NIH Grant 1R01CA196854: ALTE1621
2016CG108
AALL1521/INCB 18424-269 - A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK PathwayMutant Acute Lymphoblastic Leukemia
2016CG116
MK3475-051/ADVL1621 - A Phase I/II Study of Pembrolizumab (MK3475) in Children with Advanced Melanoma or a PDL1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE051) Additional Title: ADVL1621 Merck Sharp and Dohme Corp.
2016IS027
MT2016-33 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Corticosteroids in Patients with New Onset Chronic Graft Versus Host Disease (cGVHD)
2017CG114
COG APEC1621 - NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE) MASTER VERSION CONTROL PROTOCOL
2017CG143
COG ADVL1615 - A Phase I Study of Pevonedistat (MLN-4924, IND#136078), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors Additional Title: "COG ADVL1615 - Millennium Pharmaceuticals, Inc."
2017IS017
MT2017-07 A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord?, Ex Vivo Expanded, Umbilical Cord Blood-derived, Stem and Progenitor Cells, versus Unmanipulated Umbilical Cord Blood for Patients with Hematological Malignancies
2017NTUC078
Building Evidence for Effective Palliative/End of Life Care for Teens with Cancer: FAmily CEntered (FACE) ACP for Teens with Cancer - A multi-site Randomized Control Trial (RCT)
IDIM-2017-25460
SHP620-302: A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
IDIM-2017-25680
SHP620-303: A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
KIN-2016-25209
The Development of Limb Position Sense during Childhood
MT2006-13
MT2006-13 Autologous Peripheral Blood Stem Cell Transplant for Acute Non-Lymphocytic Leukemia (ANLL)

40 trials displayed